Abstract
The commonly deleted region (CDR) for the 5q− syndrome has been identified as a 1.5-megabase interval on human chromosome 5q32. We studied, by real-time reverse-transcription (RT)–PCR, the expression of 33 genes within the CDR that are known to be expressed in CD34+ hematopoietic stem cells. Genes in the 5q− samples that showed the most pronounced decrease in expression compared to non-5q− samples were: solute carrier family 36, member 1 (SLC36A1; 89% downregulated), Ras-GTPase-activating protein SH3 domain-binding (G3BP; 79%), antioxidant protein 1 (ATOX1; 76%), colony-stimulating factor-1 receptor precursor (CSF1R; 76%), ribosomal protein S14 (RPS14; 74%), platelet-derived growth factor receptor-β (PDGFRB; 73%), Nef-associated factor 1 (TNIP1; 72%), secreted protein, acidic and rich in cysteine (SPARC; 71%), annexin VI (ANAX6; 69%), NSDT (66%) and TIGD (60%). We further studied the hematopoietic system in SPARC-null mice. These mice showed significantly lower platelet counts compared to wild-type animals (P=0.008). Although hemoglobin, hematocrit and mean corpuscular volume (MCV) were lower in mice lacking SPARC, differences were not statistically significant. SPARC-null mice showed a significantly impaired ability to form erythroid burst-forming units (BFU-E). However, no significant differences were found in the formation of erythroid colony-forming units (CFU-E), granulocyte/monocyte colony-forming units (CFU-GM) or megakaryocyte colony-forming units (CFU-Mk) in these animals. We conclude that many of the genes within the CDR associated with the 5q− syndrome exhibit significantly decreased expression and that SPARC, as a potential tumor suppressor gene, may play a role in the pathogenesis of this disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Catenacci DV, Schiller GJ . Myelodysplasic syndromes: a comprehensive review. Blood Rev 2005; 19: 301–319.
Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4: 325–345.
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000; 108: 346–356.
Heim S, Mitelman F . Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 1986; 4: 1003–1021.
Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G . Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974; 251: 437–438.
Boultwood J, Lewis S, Wainscoat JS . The 5q− syndrome. Blood 1994; 84: 3253–3260.
Nilsson L, Astrand-Grundstrom I, Anderson K, Arvidsson I, Hokland P, Bryder D et al. Involvement and functional impairment of the CD34(+)CD38(−)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002; 100: 259–267.
Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L et al. Narrowing and genomic annotation of the commonly deleted region of the 5q−syndrome. Blood 2002; 99: 4638–4641.
Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA . Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood 1996; 88: 2665–2670.
Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa R, Larson RA et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1–1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA 1997; 94: 6948–6953.
Bradshaw AD, Sage EH . SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107: 1049–1054.
Framson PE, Sage EH . SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004; 92: 679–690.
Yan Q, Clark JI, Wight TN, Sage EH . Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J Cell Sci 2002; 115: 2747–2756.
Bradshaw AD, Graves DC, Motamed K, Sage EH . SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc Natl Acad Sci USA 2003; 100: 6045–6050.
Clezardin P, Malaval L, Ehrensperger AS, Delmas PD, Dechavanne M, McGregor JL . Complex formation of human thrombospondin with osteonectin. Eur J Biochem 1988; 175: 275–284.
Clezardin P, Malaval L, Ehrensperger AS, Delmas PD, Dechavanne M, McGregor JL . Osteonectin is an α-granule component involved with thrombospondin in platelet aggregation. J Bone Miner Res 1991; 6: 1059–1070.
Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S et al. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005; 65: 7370–7377.
Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG et al. Aberrant methylation of SPARC in human lung cancers. Br J Cancer 2005; 92: 942–948.
Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions. Oncogene 2003; 22: 5021–5030.
Koeffler HP, Golde DW . Human myeloid leukemia cell lines: a review. Blood 1980; 56: 344–350.
Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH et al. SPARC deficiency leads to early onset cataractogenesis. Invest Ophthalmol Vis Sci 1998; 39: 2674–2680.
Irvine K, Stirling R, Hume D, Kennedy D . Rasputin, more promiscuous than ever: a review of G3BP. Int J Dev Biol 2004; 48: 1065–1077.
Harris ED . Basic and clinical aspects of copper. Crit Rev Clin Lab Sci 2003; 40: 547–586.
Roussel MF, Sherr CJ . Oncogenic potential of the c-FMS proto-oncogene (CSF-1 receptor). Cell Cycle 2003; 2: 5–6.
Ebert BL, Lee MM, Pretz JL, Subramanian A, Mak R, Golub TR et al. An RNA interference model of RPS19 deficiency in Diamond–Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood 2005; 105: 4620–4626.
Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001; 159: 609–622.
Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW . Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 2002; 75: 73–85.
Bradshaw AD, Francki A, Motamed K, Howe C, Sage EH . Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 1999; 10: 1569–1579.
Francki A, Motamed K, McClure TD, Kaya M, Murri C, Blake DJ et al. SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J Cell Biochem 2003; 88: 802–811.
Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA . Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 2002; 62: 6270–6277.
Gregory CJ, Eaves AC . Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood 1978; 51: 527–537.
Chui DH, Liao SK, Walker K . Fetal erythropoiesis in steel mutant mice. III. Defect in differentiation from BFU-E to CFU-E during early development. Blood 1978; 51: 539–547.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehmann, S., O'Kelly, J., Raynaud, S. et al. Common deleted genes in the 5q− syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 21, 1931–1936 (2007). https://doi.org/10.1038/sj.leu.2404852
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404852
Keywords
This article is cited by
-
Age-related decline in LEPR+ hematopoietic stem cell function
Leukemia (2023)
-
Therapy-related myeloid neoplasms: when genetics and environment collide
Nature Reviews Cancer (2017)
-
Transcriptome meta-analysis reveals a dysregulation in extra cellular matrix and cell junction associated gene signatures during Dengue virus infection
Scientific Reports (2016)
-
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
Annals of Hematology (2014)
-
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
Oncogene (2013)